Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease-Reference-Cited by-同舟云学术

Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease

Published:2021-03-01 Issue:3 Volume:78 Page:312
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Simuni Tanya¹,Fiske Brian²,Merchant Kalpana³,Coffey Christopher S.⁴,Klingner Elizabeth⁴,Caspell-Garcia Chelsea⁴,Lafontant David-Erick⁴,Matthews Helen⁵,Wyse Richard K.⁶,Brundin Patrik⁷,Simon David K.⁸,Schwarzschild Michael⁹,Weiner David¹⁰,Adams Jamie¹¹,Venuto Charles¹²,Dawson Ted M.¹³,Baker Liana¹²,Kostrzebski Melissa¹²,Ward Tina¹,Rafaloff Gary¹⁴,Adams Jamie¹⁵,Augustine Erika¹⁵,Baker Deborah¹⁵,Brocht Alicia¹⁵,Casaceli Cindy¹⁵,Eaton Ken¹⁵,Henderson Sue¹⁵,McMullen Nichole¹⁵,Muneath Phounsavath¹⁵,Trusso Laura¹⁵,Field Carlinda¹⁵,Brahmachari Saurav¹⁵,Rosenthal Liana¹⁵,Carman Emily¹⁵,Kamp Cornelia¹⁵,Bolger Patrick¹⁵,Wegel Claire¹⁵,Reynolds Holly¹⁵,Levy Oren¹⁵,Servi Amber¹⁵,Chou Kelvin¹⁵,Stovall Angela S¹⁵,Pal Gian¹⁵,Keith Kellie¹⁵,Chung Kathryn¹⁵,Shahed Joohi¹⁵,Hunter Christine¹⁵,Shah Binit¹⁵,Sullivan Katie¹⁵,Hung Albert Y.¹⁵,Bwala Grace¹⁵,Spindler Meredith¹⁵,Oliver Alexandria¹⁵,Hauser Robert A.¹⁵,Rocha Claudia¹⁵,Molho Eric¹⁵,Evans Sharon¹⁵,Shill Holly A.¹⁵,Ismail Farah¹⁵,Stover Natividad¹⁵,Cromer Candace¹⁵,Blair Courtney¹⁵,Zhang Lin¹⁵,Kishchenko Olga¹⁵,Swan Matthew¹⁵,Ramirez Laura¹⁵,Frank Samuel¹⁵,Burrows Stephanie¹⁵,Duker Andrew¹⁵,Gruenwald Christina¹⁵,Blindauer Karen¹⁵,Wheeler Lynn¹⁵,Seeberger Lauren¹⁵,Simpson Abigail¹⁵,Scott Burton L.¹⁵,Gauger Lisa¹⁵,Ahmed Anwar¹⁵,Pitchford Yvette¹⁵,Mule Jennifer¹⁵,Ramirez-Zamora Adolfo¹⁵,Ridgeway Derek B.¹⁵,Slevin John Slevin¹⁵,Wagner Renee Wagner¹⁵,Hinson Vanessa¹⁵,Jenkins Shonna¹⁵,Goudreau John L.¹⁵,Russell Doozie¹⁵,Mari Zoltan¹⁵,Dumitrescu Lilliana¹⁵,Aldred Jason¹⁵,Bixby Melissa¹⁵,LeDoux Mark¹⁵,

Affiliation:

1. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

2. Research Programs, Michael J. Fox Foundation for Parkinson’s Research, New York, New York

3. Department of Neurology, Northwestern University, Chicago, Illinois

4. Department of Biostatistics, College of Public Health, University of Iowa, Iowa City

5. The Cure Parkinson’s Trust, London, England

6. Research and Development, The Cure Parkinson’s Trust, London, England

7. Van Andel Institute, Center for Neurodegenerative Science, Grand Rapids, Michigan

8. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts

9. Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts

10. Consultant, Austin, Texas

11. Department of Neurology, University of Rochester, Rochester, New York

12. CHET CTCC, University of Rochester, Rochester, New York

13. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland

14. Steven’s Institute of Technology, Marlboro, New Jersey

15. for the Parkinson Study Group NILO-PD Investigators and Collaborators

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2773698/jamaneurology_simuni_2020_oi_200091_1614894403.37383.pdf

Reference18 articles.

1. Epidemiology of Parkinson’s disease.;de Lau;Lancet Neurol,2006

2. Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations.;Lang;Mov Disord,2018

3. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson’s disease.;Karuppagounder;Sci Rep,2014

4. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of a-synuclein in Parkinson’s disease models.;Hebron;Hum Mol Genet,2013

5. Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in a-synucleinopathy.;Hebron;J Clin Cell Immunol,2014

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent updates on immunotherapy in neurodegenerative diseases;Brain Research;2024-12

2. Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies;Cellular and Molecular Life Sciences;2024-09-03

3. Identifying potential repurposable medications for Parkinson’s disease through Mendelian randomization analysis;Scientific Reports;2024-08-24

4. Experimental Parkinson models and green chemistry approach;Behavioural Brain Research;2024-08

5. Nilotinib treatment outcomes in autosomal dominant spinocerebellar ataxia over one year;Scientific Reports;2024-07-15